Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229154 | 0.83 | BACE1 (0.49) | ALDH1A1CYP2D6ESR1ESR2BACE1 | |
| SCHEMBL29766271 | 0.83 | BACE1 (0.49) | ALDH1A1CYP2D6ESR1ESR2BACE1 | |
| SCHEMBL29577003 | 0.80 | TSHR (0.56) | ALDH1A1ESR1ESR2BACE1TSHR | |
| SCHEMBL213758 | 0.80 | TSHR (0.56) | ALDH1A1ESR1ESR2BACE1TSHR | |
| SCHEMBL6031674 | 0.78 | MAPK1 (0.67) | ALDH1A1ESR1ESR2BACE1KDM4E | |
| SCHEMBL29395434 | 0.78 | S100A4 (0.56) | ALDH1A1CYP2D6KDM4EMAPTMAPK1 | |
| SCHEMBL6796101 | 0.78 | ESR1 (0.57) | ALDH1A1ESR1ESR2BACE1MAPT | |
| SCHEMBL69947 | 0.78 | MAPK1 (0.67) | ALDH1A1ESR1ESR2BACE1KDM4E | |
| SCHEMBL29950169 | 0.78 | ESR1 (0.57) | ALDH1A1ESR1ESR2BACE1MAPT | |
| SCHEMBL29502912 | 0.78 | MAPK1 (0.67) | ALDH1A1ESR1ESR2BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266356-B | Carbazole compound serving as autotaxin inhibitor and preparation method and application thereof | 山西省生物研究院有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-102060717-B | The synthetic method of the bromophenol of 3 amino 4 | 大连九信精细化工有限公司 | 2017-12-05 | — | — | CN | claimed |
| CN-107266356-A | It is a kind of to be used as carbazole compound of autotaxin inhibitors and its preparation method and application | 山西省生物研究所 | 2017-10-20 | — | — | CN | claimed |
| CN-102060717-A | Synthetic method of 3-amino-4-bromophenol | DS CHEMPHY INC | 2011-05-18 | — | — | CN | claimed |
| EP-0939754-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1998019648-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-05-14 | — | — | WO | claimed |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-1998012190-A2 | PHENOXATHIIN DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE | KRENITSKY PHARMACEUTICAL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0520281-B1 | Optical element for generating short wave laser light | HOFFMANN LA ROCHE (CH) | 1997-03-12 | — | — | EP | disclosed |
| US-5545568-A | ARRAY OF COMPOUNDS ON SUBSTRATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-08-13 | — | — | US | disclosed |
| US-5420123-A | Dibenzodiazepine endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-05-30 | — | — | US | disclosed |
| US-5335303-A | Quasi-phased matched optical waveguide frequency conversion element having a ferroelectric liquid crystalline material exhibiting a periodic structure | HOFFMANN-LA ROCHE INC. (US) | 1994-08-02 | — | — | US | disclosed |
| WO-1994006291-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF COMPOUNDS ON A SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0520281-A2 | Optical element for generating short wave laser light | F. HOFFMANN-LA ROCHE AG (CH) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | ALDH1A1 998/4885CYP2D6 333/4885ESR1 2376/4885 |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | ALDH1A1 2169/4885CYP2D6 1753/4885ESR1 1603/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ALDH1A1 3566/4885CYP2D6 4631/4885ESR1 2466/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | ALDH1A1 2169/4885CYP2D6 1753/4885ESR1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.